Key result
Higher PF-4var/CXCL4L1 linked to ~11% lower risk of adverse cardiovascular events in stable CAD.
Why the study?
The role and prognostic value of the platelet-derived chemokine PF-4var/CXCL4L1 in stable coronary artery disease patients with preserved left ventricular function had not been studied.
Cohort (n=205)
No
Low levels of the platelet-derived chemokine PF-4var/CXCL4L1 independently predict adverse cardiovascular outcomes in patients with stable CAD and preserved LV function, providing prognostic value beyond NT-proBNP.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for PF-4var/CXCL4L1 in stable CAD prognosis; prospective validation required before clinical adoption.
BACKGROUND: Platelet-derived chemokines are implicated in several aspects of vascular biology. However, for the chemokine platelet factor 4 variant (PF-4var/CXCL4L1), released by platelets during thrombosis and with different properties as compared to PF-4/CXCL4, its role in heart disease is not yet studied. We evaluated the determinants and prognostic value of the platelet-derived chemokines PF-4var, PF-4 and RANTES/CCL5 in patients with stable coronary artery disease (CAD). METHODOLOGY/PRINCIPAL FINDINGS: From 205 consecutive patients with stable CAD and preserved left ventricular (LV) function, blood samples were taken at inclusion and were analyzed for PF-4var, RANTES, platelet factor-4 and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Patients were followed (median follow-up 2.5 years) for the combined endpoint of cardiac death, non-fatal acute myocardial infarction, stroke or hospitalization for heart failure. Independent determinants of PF-4var levels (median 10 ng/ml; interquartile range 8-16 ng/ml) were age, gender and circulating platelet number. Patients who experienced cardiac events (n = 20) during follow-up showed lower levels of PF-4var (8.5 [5.3-10] ng/ml versus 12 [8-16] ng/ml, p = 0.033). ROC analysis for events showed an area under the curve (AUC) of 0.82 (95% CI 0.73-0.90, p<0.001) for higher NT-proBNP levels and an AUC of 0.32 (95% CI 0.19-0.45, p = 0.009) for lower PF-4var levels. Cox proportional hazard analysis showed that PF-4var has an independent prognostic value on top of NT-proBNP. CONCLUSIONS: We conclude that low PF-4var/CXCL4L1 levels are associated with a poor outcome in patients with stable CAD and preserved LV function. This prognostic value is independent of NT-proBNP levels, suggesting that both neurohormonal and platelet-related factors determine outcome in these patients.
No takes yet. Share an insight, caveat, or question.
Sutter et al. (2012) conducted a cohort in Stable Coronary Artery Disease (n=205). PF-4var/CXCL4L1 levels vs. Higher PF-4var levels was evaluated on Combined endpoint of cardiac death, non-fatal acute myocardial infarction, stroke or hospitalization for heart failure (HR 0.89, 95% CI 0.79-0.99, p=0.036). Higher levels of PF-4var/CXCL4L1 were independently associated with a reduced risk of adverse cardiovascular events in patients with stable coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: